NCI-H460 cells with mutant PIK3CA and KRASgenes. Finally, the effect of radiation on EMT-associated markers was also assessed, revealing that mTORC1 inhibition couldalleviate irradiation-specific EMT changesin NCI-H661 cells. Conclusion: these data suggest that mTORC1 inhibition in NSCLC may enhance radiosensitivity by affecting the expression of EMT-associated proteins.This suggests targeting mTORC1 may provide a potential new strategy for the treatment of NSCLC with wildtype PIK3CA and KRAS genes.
P3.01-15 Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated Y. Chen, 1 Y. Tseng, 2 J. Shih, 1 H. Chao 1 1 Department of Chest Medicine, Taipei Veterans General Hospital, Taipei/TW, 2 Shuang-Ho Hospital, Ministry of Health and Welfare, New Taipei City/TW Background: Salvage chemotherapy is frequently used. However, the efficacy of salvage chemotherapy of paclitaxel plus TS1 (TTS1) is still unknown. Method: We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor EGFR mutation, response to first-line EGFR-TKI treatment or not, and efficacies of TTS1, were collected. Result: Total 25 patients were enrolled in this study. No patients archived complete response and six patients had partial response (ORR: 24%). The disease control rate was 60% (15/25). The progression free survival (PFS) was 4.8 months and overall survival (OS) was 12.4 months. Among these 25 patients that received TTS1, 17 of them had driver mutations. Patients with driver mutations had better PFS (4.9 months vs 1.8 months) and OS (15.5 months vs 7.2 months) compared with those without driver mutations. Conclusion: TTS1 are effective salvage chemotherapeutic agents, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more efficient salvage treatment strategy is found. Keywords: non-small cell lung cancer, S-1, EGFR P3.01-16 Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure M. Chen, J. Song, W. Liu Department of Chemoradiotherapy, Tangshan People'S Hospital, Tangshan/CN Background: EGFR TKIs have been approved as the first-line therapy for treating advanced non-small-cell lung cancer (NSCLC). However, treatment failures frequently occurred in NSCLC patients with EGFRsensitizing mutations. Apatinib, a novel small molecule TKI targeted VEGFR2, recommended as third-line treatment for metastatic gastric cancer patients. This retrospective study tried to investigate the efficacy and safety of low dose Apatinib combined with original targeted drugs in treating advanced NSCLC after first-generation EGFR-TKIs treatment failure and trying to explore the underlying mechanisms. Method: From March 2016 to November 2016, 11 patients of advanced NSCLC acquired resistance for Erlotinib, gefitinib and Icotinib treated with original targeted drugs plus Apatinib (250 mg, once daily), and CT scan every 4 weeks. Meanwhile observe drug-related adverse events. Result: In 11 patients, there were 10 patients available for efficacy and safety evaluation. 2 of 10 patients were progress disease in 12 weeks, 8 of 10 patients were stable disease and still in treatment. The disease control rate (DCR) was 80%. The rate of PFS at 12 weeks was 72.73%. The most frequent treatment-related adverse events were fatigue (20%, 2/10), rash (20%, 2/10), poor appetite (20%, 2/10), respectively. Severe AEs included grade 3 proteinuria (10%, 1/10). Conclusion: Low dose Apatinib combined with original targeted drugs is efficacious in treating patients with advanced NSCLC who failed to first-generation EGFR-TKIs treatment, with acceptable toxic effects. The mechanism may be related to Apatinib regulate tumor microenvironment and reverses multidrug resistance. Keywords: low dose Apatinib; Advanced NSCLC; first generation EGFR-TKIs; tumor microenvironment P3.01-17 Long Survivors with Advanced Lung Cancer -Efficacy and Tolerability of Nivolumab E. Chmielowska, A. Krause, M. Olejniczak, M. Swiezynski, J. Kopec Clinical Oncology, Oncology Center, Bydgoszcz/PL Background: The group of the patients with advanced lung cancer surviving more than two years was limitated, particullary at era of the classic chemotherapy.In our material presented in 2013 on WCLC it made up 11%.The differences in efficacy betweeen Nivolumab and conventional treatment in pretreated patients remains unclear, particullary in the group with good response on chemotherapy with long interval between lines. We analyzed the efficacy and tolerance of Nivolumab in the long surviving group. Method: 7 patients characterized by long earlier history of lung cancer were found. Baseline characteristic and historical treatment data are presented in table 1. Result: Table nr 2 presents the efficacy and tolerability of Nivolumab. The patients obtained 190 injections of drug and only one patient requires 2,5 months break beacuse of typical AE-tyreoiditis G3. Other short breaks were dependent on personal requests ,not from AE. Treatment time is 12-17 months and is plannig to continue .No progression has been noticed. Follow-up is planned. Conclusion: Long surviving patients with significant interval between chemotherapy lines show excellent tolerability and good efficacy of Nivolumab regardless of the type of previous chemotherapy.Efficacy and tolerance of these patients are comparable to described group with better prognosis from trials Checkmate 003 and 153 Keywords: Nivolumab, long survivors, NSCLC
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